• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

    11/14/24 5:48:11 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PACB alert in real time by email
    SC 13G/A 1 tm2427620d17_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

    Pacific Biosciences of California, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    69404D108

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    CUSIP No.   69404D108

    1.

    Names of Reporting Persons

    Madrone Opportunity Fund, L.P.

    2. Check the Appropriate Box if a Member of a Group (see instructions)
      (a)
      (b) x (1)
    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    23,391,915 Shares (2)

    6.

    Shared Voting Power

    0 Shares

    7.

    Sole Dispositive Power

    23,391,915 Shares (2)

    8.

    Shared Dispositive Power

    0 Shares

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    23,391,915 Shares (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

    ¨
    11.

    Percent of Class Represented by Amount in Row 9

    8.6% (3)

    12.

    Type of Reporting Person (see instructions)

    PN

     

    (1)This Schedule 13G is filed by Madrone Opportunity Fund, L.P. (“Madrone”), Madrone Capital Partners, LLC (“Madrone GP”), Shimoda Holdings, LLC (“Shimoda”), Greg Penner (“Penner”), Jameson McJunkin (“McJunkin”) and Thomas Patterson (“Patterson” and, together with the Madrone, Madrone GP, Shimoda, Penner and McJunkin, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The shares are held by Madrone. Madrone GP is the general partner of Madrone. Penner, McJunkin and Patterson are managers of Madrone GP and share voting and dispositive power over the shares held by Madrone.

     

    (3)This percentage is calculated based on 272,528,950 shares of the Issuer’s stock outstanding as of July 31, 2024, as set forth in the Issuer’s Quarterly Reporting on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission on August 9, 2024.

      

    Page 2 of 10 pages

     

     

    CUSIP No.   69404D108

    1.

    Names of Reporting Persons

    Madrone Capital Partners, LLC

    2.

    Check the Appropriate Box if a Member of a Group (see instructions) 

      (a)
      (b) x (1)
    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0 Shares

    6.

    Shared Voting Power

    23,391,915 Shares (2)

    7.

    Sole Dispositive Power

    0 Shares

    8.

    Shared Dispositive Power

    23,391,915 Shares (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    23,391,915 Shares (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

    ¨
    11.

    Percent of Class Represented by Amount in Row 9

    8.6% (3)

    12.

    Type of Reporting Person (see instructions)

    OO

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The shares are held by Madrone. Madrone GP is the general partner of Madrone. Penner, McJunkin and Patterson are managers of Madrone GP and share voting and dispositive power over the shares held by Madrone.

     

    (3)This percentage is calculated based on 272,528,950 shares of the Issuer’s stock outstanding as of July 31, 2024, as set forth in the Issuer’s Quarterly Reporting on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission on August 9, 2024.

     

    Page 3 of 10 pages

     

     

    CUSIP No.   69404D108

    1.

    Names of Reporting Persons

    Shimoda Holdings, LLC

    2.

    Check the Appropriate Box if a Member of a Group (see instructions) 

      (a)
      (b) x (1)
    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0 Shares

    6.

    Shared Voting Power

    3,500,000 Shares (2)

    7.

    Sole Dispositive Power

    0 Shares

    8.

    Shared Dispositive Power

    3,500,000 Shares (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,500,000 Shares (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

    ¨
    11.

    Percent of Class Represented by Amount in Row 9

    1.3% (3)

    12.

    Type of Reporting Person (see instructions)

    OO

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The shares are held by Shimoda. Penner is a Vice President and Manager of Shimoda and shares voting and dispositive power over the shares held by Shimoda.

     

    (3)This percentage is calculated based on 272,528,950 shares of the Issuer’s stock outstanding as of July 31, 2024, as set forth in the Issuer’s Quarterly Reporting on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission on August 9, 2024.

     

    Page 4 of 10 pages

     

     

    CUSIP No.   69404D108

    1.

    Names of Reporting Persons

    Greg Penner

    2.

    Check the Appropriate Box if a Member of a Group (see instructions) 

      (a)
      (b) x (1)
    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0 Shares

    6.

    Shared Voting Power

    26,891,915 Shares (2)

    7.

    Sole Dispositive Power

    0 Shares

    8.

    Shared Dispositive Power

    26,891,915 Shares (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    26,891,915 Shares (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

    ¨
    11.

    Percent of Class Represented by Amount in Row 9

    9.9% (3)

    12.

    Type of Reporting Person (see instructions)

    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Includes (i) 23,391,915 shares held by Madrone and (ii) 3,500,000 shares held by Shimoda. Madrone GP is the general partner of Madrone. Penner, McJunkin and Patterson are managers of Madrone GP and share voting and dispositive power over the shares held by Madrone. Penner is a Vice President and Manager of Shimoda and shares voting and dispositive power over the shares held by Shimoda.

     

    (3)This percentage is calculated based on 272,528,950 shares of the Issuer’s stock outstanding as of July 31, 2024, as set forth in the Issuer’s Quarterly Reporting on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission on August 9, 2024.

      

    Page 5 of 10 pages

     

     

    CUSIP No.   69404D108

    1.

    Names of Reporting Persons

    Jameson McJunkin

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

      (a)
      (b) x (1)
    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0 Shares

    6.

    Shared Voting Power

    23,391,915 Shares (2)

    7.

    Sole Dispositive Power

    0 Shares

    8.

    Shared Dispositive Power

    23,391,915 Shares (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    23,391,915 Shares (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

    ¨
    11.

    Percent of Class Represented by Amount in Row 9

    8.6% (3)

    12.

    Type of Reporting Person (see instructions)

    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The shares are held by Madrone. Madrone GP is the general partner of Madrone. Penner, McJunkin and Patterson are managers of Madrone GP and share voting and dispositive power over the shares held by Madrone.

     

    (3)This percentage is calculated based on 272,528,950 shares of the Issuer’s stock outstanding as of July 31, 2024, as set forth in the Issuer’s Quarterly Reporting on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission on August 9, 2024.

      

    Page 6 of 10 pages

     

     

    CUSIP No.   69404D108

    1.

    Names of Reporting Persons

    Thomas Patterson

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

      (a)
      (b) x (1)
    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0 Shares

    6.

    Shared Voting Power

    23,391,915 Shares (2)

    7.

    Sole Dispositive Power

    0 Shares

    8.

    Shared Dispositive Power

    23,391,915 Shares (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    23,391,915 Shares (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

    ¨
    11.

    Percent of Class Represented by Amount in Row 9

    8.6% (3)

    12.

    Type of Reporting Person (see instructions)

    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The shares are held by Madrone. Madrone GP is the general partner of Madrone. Penner, McJunkin and Patterson are managers of Madrone GP and share voting and dispositive power over the shares held by Madrone.

     

    (3)This percentage is calculated based on 272,528,950 shares of the Issuer’s stock outstanding as of July 31, 2024, as set forth in the Issuer’s Quarterly Reporting on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission on August 9, 2024.

     

    Page 7 of 10 pages

     

     

    Item 1(a).

    Name of Issuer:

     

    Pacific Biosciences of California, Inc.

       
    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

     

    1305 O’Brien Drive, Menlo Park, CA 94025

       
    Item 2(a).

    Name of Person Filing:

     

    Madrone Opportunity Fund, L.P. (“Madrone”)
    Madrone Capital Partners, LLC (“Madrone GP”)
    Shimoda Holdings, LLC (“Shimoda”)
    Greg Penner (“Penner”)
    Jameson McJunkin (“McJunkin”)
    Thomas Patterson (“Patterson”)

       
    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

     

    1149 Chestnut Street, Suite 200, Menlo Park, CA 94025

       
    Item 2(c).

    Citizenship:

     

    All entities were organized in Delaware

    All individuals are United States Citizens

       
    Item 2(d).

    Title of Class of Securities:

     

    Common Stock

       
    Item 2(e).

    CUSIP Number:

     

    69404D108

       
    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

       
    Item 4. Ownership
       
      The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of November 14, 2024:

     

    Fund Entities  Shares Held
    Directly
       Sole
    Voting
    Power
       Shared Voting Power   Sole
    Dispositive
    Power
       Shared
    Dispositive
    Power
       Beneficial
    Ownership
       Percentage
    of Class (3)
     
    Madrone (1)   23,391,915    0    23,391,915    0    23,391,915    23,391,915    8.6%
    Madrone GP (1)   0    0    23,391,915    0    23,391,915    23,391,915    8.6%
    Shimoda (2)   3,500,000    0    3,500,000    0    3,500,000    3,500,000    1.3%
    Penner (1) (2)   0    0    26,891,915    0    26,891,915    26,891,915    9.9%
    McJunkin (1)   0    0    23,391,915    0    23,391,915    23,391,915    8.6%
    Patterson (1)   0    0    23,391,915    0    23,391,915    23,391,915    8.6%

     

    (1)Includes 23,391,915 shares held by Madrone. Madrone GP is the general partner of Madrone. Penner, McJunkin and Patterson are managers of Madrone GP and share voting and dispositive power over the shares held by Madrone.
    (2)Includes 3,500,000 shares held by Shimoda. Penner is a Vice President and Manager of Shimoda and shares voting and dispositive power over the shares held by Shimoda.
    (3)This percentage is calculated based on 272,528,950 shares of the Issuer’s stock outstanding as of July 31, 2024, as set forth in the Issuer’s Quarterly Reporting on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission on August 9, 2024.

     

    Page 8 of 10 pages

     

      

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
       
    Item 9. Notice of Dissolution of Group
       
      Not applicable
       
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

    Page 9 of 10 pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Madrone Opportunity Fund, L.P.  
       
    By: Madrone Capital Partners, LLC  
    Its   General Partner  
       
    By: /s/ Greg Penner  
      Name: Greg Penner  
      Title: Manager  
       
    Madrone Capital Partners, LLC  
       
    By: /s/ Greg Penner  
      Name: Greg Penner  
      Title: Manager  
       
    Shimoda Holdings, LLC  
       
    By: /s/ Greg Penner  
      Name: Greg Penner  
      Title: Vice President and Manager  
       
    /s/ Greg Penner  
    Greg Penner  
       
    /s/ Thomas Patterson  
    Thomas Patterson  
       
    /s/ Jameson McJunkin  
    Jameson McJunkin  

     

    Page 10 of 10 pages

     

    Get the next $PACB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PACB

    DatePrice TargetRatingAnalyst
    11/11/2024Buy → Neutral
    UBS
    6/3/2024$4.00Buy
    Jefferies
    4/22/2024Overweight → Neutral
    JP Morgan
    4/18/2024$7.00 → $2.50Buy → Neutral
    Goldman
    12/14/2023$11.00Overweight
    Stephens
    12/14/2023Neutral
    Guggenheim
    12/13/2023Peer Perform
    Wolfe Research
    11/17/2023$13.00 → $10.00Neutral → Buy
    UBS
    More analyst ratings

    $PACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pacific Biosciences downgraded by UBS

    UBS downgraded Pacific Biosciences from Buy to Neutral

    11/11/24 9:44:33 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jefferies resumed coverage on Pacific Biosciences with a new price target

    Jefferies resumed coverage of Pacific Biosciences with a rating of Buy and set a new price target of $4.00

    6/3/24 8:16:36 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Pacific Biosciences downgraded by JP Morgan

    JP Morgan downgraded Pacific Biosciences from Overweight to Neutral

    4/22/24 7:40:44 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PacBio Announces Second Quarter 2025 Financial Results

    MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results:  Q2 2025Q2 2024Revenue$39.8 million$36.0 millionInstrument revenue$14.2 million$14.7 millionConsumable revenue$18.9 million$17.0 millionService and other revenue$6.7 million$4.3 millionRevio™ systems1524Vega™ systems38—Annualized Revio pull-through per system~$219,000~$251,000Cash, cash equivalents, and investments$314.7 million$509.8 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspo

    8/7/25 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio to Present at Upcoming Investor Conferences

    MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 2:30 PM ET in Boston, MAMorgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 12:20 PM ET in New York, NY Live webcasts of the events can be accessed at the company's investors page at investor.pacificbiosciences.com. A replay of the webcasts will be available for at least 30 days following the event. About PacBio PacBio

    8/6/25 9:00:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models

    MENLO PARK, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of a study published in Nature Methods describing a new, comprehensive truth-set of genomic variation which characterizes simple and complex variation. These improved benchmarks were used to retrain Google's DeepVariant, a popular AI-based variant calling tool, resulting in a 34% reduction in erroneously called variants. This resource (the Platinum Pedigree) was built by scientists from PacBio in collaboration with researchers at the University of Washington, the University of Utah, and several other institutions.

    8/4/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    SEC Filings

    View All

    SEC Form S-8 filed by Pacific Biosciences of California Inc.

    S-8 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    8/7/25 4:51:37 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Pacific Biosciences of California Inc.

    10-Q - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    8/7/25 4:38:41 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Pacific Biosciences of California Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    8/7/25 4:12:59 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Meline David W bought $176,160 worth of shares (40,000 units at $4.40) (SEC Form 4)

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/6/24 5:36:07 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mohr Marshall

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    6/6/25 4:10:59 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Livingston Randall S

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    6/6/25 4:10:13 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Ordonez Kathy

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    6/6/25 4:09:30 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Leadership Updates

    Live Leadership Updates

    View All

    PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

    MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access to PacBio's HiFi long-read sequencing technology in clinical and research settings, with a focus on transfusion medicine and hematology, areas where precision and completeness of genomic data are critical to patient outcomes. Founded in 2020, Haorui Gene has quickly become a key player in blood typing genomics, deploying seven Sequel II and three R

    5/22/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jim Gibson to join PacBio as Chief Financial Officer

    MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations. Mr. Gibson joins PacBio from Sequoia, a strategic compensation and benefits solutions provider, where he served as CFO across

    3/27/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service

    MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communication solutions for business and mobile operators. In his role he led North American sales for the enterprise, mid-market segments. Before that, he held senior sales positions at Zoom V

    2/3/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Financials

    Live finance-specific insights

    View All

    PacBio Announces Second Quarter 2025 Financial Results

    MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results:  Q2 2025Q2 2024Revenue$39.8 million$36.0 millionInstrument revenue$14.2 million$14.7 millionConsumable revenue$18.9 million$17.0 millionService and other revenue$6.7 million$4.3 millionRevio™ systems1524Vega™ systems38—Annualized Revio pull-through per system~$219,000~$251,000Cash, cash equivalents, and investments$314.7 million$509.8 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspo

    8/7/25 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025

    MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2025 financial results on Thursday, August 7, 2025, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, August 7, 2025, at 5:00 pm ET (2:00 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBio Q2

    7/21/25 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio Announces First Quarter 2025 Financial Results

    MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:  Q1 2025Q1 2024Revenue$37.2 million$38.8 millionInstrument revenue$11.0 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio™ systems1228Vega™ systems28—Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspon

    5/8/25 4:15:34 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/26/24 8:27:01 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:52:54 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

    SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:48:11 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials